AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16325020 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous combined regimen: combined oestrogen/progestogen skin patches (releasing continuous 50 microg estradiol and 20 microg levonorgestrel/day)
Number of subjects: 59
Study 16325020 — intervention group
Group type: COMPARATOR
Intervention: Interrupted regimen: oestrogen-only patches (releasing 80 microg estradiol/day) for 4 days followed by combined oestrogen/progestogen patches (releasing continuous 50 microg estradiol and 20 microg levonorgestrel/day) for 3 days
Number of subjects: 59
Study 14623524 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 0
Study 14623524 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 0
Study 14623524 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole and Anastrozole
Number of subjects: 0
Study 14623524 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-conserving surgery and radiotherapy
Number of subjects: 0
Study 10824665 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory factor analyses in group A
Number of subjects: 1472
Study 10824665 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmatory factor analyses in group B
Number of subjects: 1472
Study 10824665 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-factor model with 12 items (W-BQ12)
Number of subjects: 1472
Study 8787175 — intervention group
Group type: EXPERIMENTAL
Intervention: Relevant condition (counting stimuli)
Number of subjects: 2
Study 8787175 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrelevant condition (ignoring stimuli)
Number of subjects: 2
Study 8787175 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-RT subjects
Number of subjects: 2
Study 2050424 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg three times daily)
Number of subjects: 128
Study 2050424 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (960 mg three times daily)
Number of subjects: 128
Study 6338840 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for 7 days
Number of subjects: 13
Study 6338840 — intervention group
Group type: COMPARATOR
Intervention: Control regimen
Number of subjects: 13
Study 30713016 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Degludec
Number of subjects: 0
Study 30713016 — intervention group
Group type: COMPARATOR
Intervention: Insulin Glargine
Number of subjects: 0
Study 27862066 — intervention group
Group type: EXPERIMENTAL
Intervention: AFXL treatment
Number of subjects: 12
Study 27862066 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated scars)
Number of subjects: 12
Study 26399603 — intervention group
Group type: EXPERIMENTAL
Intervention: Early physical therapy for the first 4 weeks
Number of subjects: 220
Study 26399603 — intervention group
Group type: COMPARATOR
Intervention: Usual care only for the first 4 weeks
Number of subjects: 220
Study 22730470 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesogaberan 60 mg twice daily
Number of subjects: 661
Study 22730470 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesogaberan 120 mg twice daily
Number of subjects: 661
Study 22730470 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesogaberan 180 mg twice daily
Number of subjects: 661
Study 22730470 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesogaberan 240 mg twice daily
Number of subjects: 661
Study 22730470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 661
Study 20942820 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centred approaches to nursing care practices (PCC)
Number of subjects: 605
Study 20942820 — intervention group
Group type: EXPERIMENTAL
Intervention: Modifications to physical environment (PCE)
Number of subjects: 605
Study 20942820 — intervention group
Group type: EXPERIMENTAL
Intervention: PCC + PCE
Number of subjects: 605
Study 20942820 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 605
Study 20942820 — intervention group
Group type: COMPARATOR
Intervention: Usual Environment (UE)
Number of subjects: 605
Study 19167011 — intervention group
Group type: EXPERIMENTAL
Intervention: New algorithm for predicting the culprit artery from ECG in inferior STEMI
Number of subjects: 187
Study 19167011 — intervention group
Group type: COMPARATOR
Intervention: Previous algorithm for predicting the culprit artery from ECG in all-comers STEMI
Number of subjects: 187
Study 16737869 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral erythromycin (EM) 10 mg/kg every 6 hours for 2 days, followed by 4 mg/kg every 6 hours for another 5 days
Number of subjects: 46
Study 16737869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 15514409 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT (suprathreshold right unilateral or bilateral ECT)
Number of subjects: 139
Study 11444418 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated garlic powder tablets with 9.6 mg allicin-releasing potential
Number of subjects: 46
Study 11444418 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo tablets
Number of subjects: 46
Study 9272801 — intervention group
Group type: EXPERIMENTAL
Intervention: TMD group (Hi-SC TMD)
Number of subjects: 75
Study 9272801 — intervention group
Group type: EXPERIMENTAL
Intervention: TMD group (Lo-SC TMD)
Number of subjects: 75
Study 9272801 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study 9120818 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil suspension without sodium lauryl sulfate (SLS)
Number of subjects: 24
Study 9120818 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil suspension with sodium lauryl sulfate (SLS)
Number of subjects: 24
Study 9120818 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime axetil tablet formulation
Number of subjects: 24
Study 2884853 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 297
Study 2884853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 297
Study 2884853 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 297
Study 31962179 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-ICU cold intravenous (i.v.) fluids
Number of subjects: 352
Study 31962179 — intervention group
Group type: COMPARATOR
Intervention: No pre-ICU cold intravenous (i.v.) fluids
Number of subjects: 352
Study 31690740 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-evening bright light exposure (1200 lx, 4000 K) for 2.5 hours
Number of subjects: 12
Study 31690740 — intervention group
Group type: COMPARATOR
Intervention: Late-evening light exposure (750 lx, 4000 K)
Number of subjects: 12
Study 31690740 — intervention group
Group type: COMPARATOR
Intervention: Dim light
Number of subjects: 12
Study 29208784 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX) mouthwash
Number of subjects: 60
Study 29208784 — intervention group
Group type: EXPERIMENTAL
Intervention: Neem mouthwash
Number of subjects: 60
Study 29208784 — intervention group
Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 60
Study 26163375 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-controlled feedback (Self)
Number of subjects: 0
Study 26163375 — intervention group
Group type: COMPARATOR
Intervention: Yoked feedback (Yoked)
Number of subjects: 0
Study 23343363 — intervention group
Group type: EXPERIMENTAL
Intervention: Client-centred occupational therapy (OT)
Number of subjects: 269
Study 23343363 — intervention group
Group type: COMPARATOR
Intervention: Usual care OT
Number of subjects: 269
Study 21617527 — intervention group
Group type: EXPERIMENTAL
Intervention: L-theanine (400 mg/d)
Number of subjects: 40
Study 21617527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 18158312 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatin solution
Number of subjects: 66
Study 18158312 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) (130/0.4)
Number of subjects: 66
Study 18158312 — intervention group
Group type: COMPARATOR
Intervention: Ringer's lactate solution
Number of subjects: 66
Study 17347346 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite measure of self-regulation (youth, parent, teacher report)
Number of subjects: 0
Study 14521738 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem infusion (0.1 mg/kg/h)
Number of subjects: 40
Study 10627344 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioabsorbable polyglyconate screw (Endo‐Fix; Smith & Nephew, Andover, MA)
Number of subjects: 124
Study 10627344 — intervention group
Group type: COMPARATOR
Intervention: Metal screw
Number of subjects: 124
Study 9407509 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose lisinopril (group 1)
Number of subjects: 25
Study 9407509 — intervention group
Group type: COMPARATOR
Intervention: No ACE inhibitor therapy (group 2)
Number of subjects: 25
Study 9407509 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 25
Study 1362778 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric coated sulfasalazine as Salazopyrin En‐tabs
Number of subjects: 105
Study 1362778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 2862808 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 2.5 mg
Number of subjects: 100
Study 2862808 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 5 mg
Number of subjects: 100
Study 2862808 — intervention group
Group type: EXPERIMENTAL
Intervention: Fazadinium 3.75 mg
Number of subjects: 100
Study 2862808 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 100
Study 30654658 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion-oriented coping style
Number of subjects: 54
Study 30654658 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological distress assessment using HADS
Number of subjects: 54
Study 29321141 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary, aerobic, motor-cognitive and intensive rehabilitation treatment (MIRT) for 4 weeks
Number of subjects: 186
Study 29321141 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rehabilitation)
Number of subjects: 186
Study 27497716 — intervention group
Group type: EXPERIMENTAL
Intervention: qPCR
Number of subjects: 4
Study 27497716 — intervention group
Group type: EXPERIMENTAL
Intervention: NGS
Number of subjects: 4
Study 25378424 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of autologous bone marrow mononuclear stem cells (BMSCs)
Number of subjects: 120
Study 25378424 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 120
Study 25378424 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 120
Study 22045413 — intervention group
Group type: EXPERIMENTAL
Intervention: Active recovery (cycling at 30% VO(2 max))
Number of subjects: 13
Study 22045413 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES (1 Hz/500 μs‐ON:OFF 2:6 s)
Number of subjects: 13
Study 22045413 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery (seated)
Number of subjects: 13
Study 19533583 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (11 homes)
Number of subjects: 17
Study 19533583 — intervention group
Group type: COMPARATOR
Intervention: Control group (6 homes)
Number of subjects: 17
Study 17651149 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose inhaled corticosteroids (ICS)
Number of subjects: 20
Study 17651149 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic steroid-free asthmatics
Number of subjects: 20
Study 17651149 — intervention group
Group type: COMPARATOR
Intervention: Non-asthmatic controls
Number of subjects: 20
Study 16092896 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential cognitive therapy (ExCT), 4 sessions
Number of subjects: 40
Study 16092896 — intervention group
Group type: COMPARATOR
Intervention: Panic control program (PCP), 12 sessions
Number of subjects: 40
Study 16092896 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential cognitive therapy (ExCT)
Number of subjects: 40
Study 16092896 — intervention group
Group type: COMPARATOR
Intervention: Panic control program (PCP)
Number of subjects: 40
Study 12071157 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11359306 — intervention group
Group type: EXPERIMENTAL
Intervention: Astra Tech implants
Number of subjects: 66
Study 11359306 — intervention group
Group type: COMPARATOR
Intervention: Brånemark System implants
Number of subjects: 66
Study 11359306 — intervention group
Group type: EXPERIMENTAL
Intervention: Both systems
Number of subjects: 66
Study 7810934 — intervention group
Group type: EXPERIMENTAL
Intervention: Relatives of patients with sleep apnea-hypopnea syndrome
Number of subjects: 102
Study 2194004 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopanoic acid (1 gm daily for 21 days)
Number of subjects: 5
Study 103852 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental cones containing the antifibrinolytically active propylic ester of p‐hydroxybenzoic acid (PEPH)
Number of subjects: 95
Study 103852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 103852 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfanilamide and sulfathiazol
Number of subjects: 95
Study 29943271 — intervention group
Group type: EXPERIMENTAL
Intervention: SLOWB (device-guided slow breathing)
Number of subjects: 21
Study 29943271 — intervention group
Group type: COMPARATOR
Intervention: No SLOWB (control group)
Number of subjects: 21
Study 28740376 — intervention group
Group type: EXPERIMENTAL
Intervention: FP/FORM 500/20 µg
Number of subjects: 1765
Study 28740376 — intervention group
Group type: EXPERIMENTAL
Intervention: FP/FORM 250/10 µg
Number of subjects: 1765
Study 28740376 — intervention group
Group type: EXPERIMENTAL
Intervention: FP/FORM 500/20 µg and FP/FORM 250/10 µg
Number of subjects: 1765
Study 28740376 — intervention group
Group type: COMPARATOR
Intervention: FP/FORM 500/20 µg, FP/FORM 250/10 µg, FORM
Number of subjects: 1765
Study 24896141 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 19
Study 24896141 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 19
Study 23386653 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (PRED) 7.5 mg once daily (n = 12)
Number of subjects: 32
Study 23386653 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (PRED) 30 mg once daily (n = 12)
Number of subjects: 32
Study 23386653 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 8)
Number of subjects: 32
Study 20955266 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg once daily
Number of subjects: 8000
Study 19710500 — intervention group
Group type: EXPERIMENTAL
Intervention: laromustine and high-dose cytarabine (HDAC)
Number of subjects: 263
Study 19710500 — intervention group
Group type: COMPARATOR
Intervention: high-dose cytarabine/placebo
Number of subjects: 263
Study 17240287 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mcg daily oral folic acid
Number of subjects: 818
Study 17240287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 818
Study 15566917 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid balance and volume administered on postoperative day 2
Number of subjects: 0
Study 15566917 — intervention group
Group type: EXPERIMENTAL
Intervention: Net fluid balance on postoperative day 2
Number of subjects: 0
Study 12488264 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost once daily
Number of subjects: 602
Study 12488264 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost twice daily
Number of subjects: 602
Study 12488264 — intervention group
Group type: COMPARATOR
Intervention: Timolol twice daily
Number of subjects: 602
Study 10450256 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0
Study 10450256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8651067 — intervention group
Group type: EXPERIMENTAL
Intervention: Onset of deafness before 18 months of age
Number of subjects: 42
Study 8651067 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger children
Number of subjects: 42
Study 8651067 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-esteem
Number of subjects: 42
Study 8651067 — intervention group
Group type: EXPERIMENTAL
Intervention: External locus of control
Number of subjects: 42
Study 2112634 — intervention group
Group type: EXPERIMENTAL
Intervention: Modular tube feeding recipe (MTF)
Number of subjects: 50
Study 2112634 — intervention group
Group type: COMPARATOR
Intervention: Enteral regimens widely utilized in the nutritional support of burns
Number of subjects: 50
Study 496555 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-free state serum calcium levels in patients with EPS
Number of subjects: 22
Study 496555 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-free state serum magnesium levels in patients with EPS
Number of subjects: 22
Study 496555 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptic dosage
Number of subjects: 22
Study 496555 — intervention group
Group type: COMPARATOR
Intervention: Serum calcium and magnesium levels during neuroleptic treatment
Number of subjects: 22
Study 31931623 — intervention group
Group type: EXPERIMENTAL
Intervention: Threat agency
Number of subjects: 276
Study 31931623 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdependent self‐construal
Number of subjects: 276
Study 31931623 — intervention group
Group type: COMPARATOR
Intervention: Independent self‐construal
Number of subjects: 276
Study 31897708 — intervention group
Group type: EXPERIMENTAL
Intervention: NAPP application into the pockets, adjunctive to NSPT
Number of subjects: 25
Study 31897708 — intervention group
Group type: COMPARATOR
Intervention: NSPT alone (Control)
Number of subjects: 25
Study 30458126 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-pulse CO2 laser resurfacing
Number of subjects: 20
Study 30458126 — intervention group
Group type: COMPARATOR
Intervention: Manual dermabrasion
Number of subjects: 20
Study 28698947 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body cryotherapy at ‐110 °C
Number of subjects: 60
Study 28698947 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body cryotherapy at ‐60 °C
Number of subjects: 60
Study 28698947 — intervention group
Group type: EXPERIMENTAL
Intervention: Local cryotherapy
Number of subjects: 60
Study 25656426 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol
Number of subjects: 543
Study 25656426 — intervention group
Group type: COMPARATOR
Intervention: Control (no xylitol)
Number of subjects: 543
Study 23351036 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 0
Study 23351036 — intervention group
Group type: EXPERIMENTAL
Intervention: d,l-sotalol
Number of subjects: 0
Study 23351036 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 0
Study 21882343 — intervention group
Group type: EXPERIMENTAL
Intervention: in vivo silencing of miR-21 using a tiny seed-targeting LNA
Number of subjects: 0
Study 21882343 — intervention group
Group type: EXPERIMENTAL
Intervention: treatment with anti-miR-21
Number of subjects: 0
Study 19122476 — intervention group
Group type: EXPERIMENTAL
Intervention: HX575 (100 IU/kg body weight, subcutaneous, 3 times weekly for 4 weeks)
Number of subjects: 80
Study 19122476 — intervention group
Group type: COMPARATOR
Intervention: Comparator epoetin alfa (100 IU/kg body weight, subcutaneous, 3 times weekly for 4 weeks)
Number of subjects: 80
Study 19122476 — intervention group
Group type: EXPERIMENTAL
Intervention: HX575
Number of subjects: 80
Study 19122476 — intervention group
Group type: COMPARATOR
Intervention: Comparator epoetin alfa
Number of subjects: 80
Study 19122476 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 80
Study 17525168 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosaprepitant 115 mg
Number of subjects: 0
Study 17525168 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosaprepitant up to 150 mg (1 mg/mL)
Number of subjects: 0
Study 17525168 — intervention group
Group type: COMPARATOR
Intervention: Aprepitant 125 mg
Number of subjects: 0
Study 16113431 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICSs) such as fluticasone
Number of subjects: 0
Study 16113431 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICSs)
Number of subjects: 0
Study 11165880 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 562
Study 11165880 — intervention group
Group type: COMPARATOR
Intervention: Parenteral Nutrition (TPN)
Number of subjects: 562
Study 9734729 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated soy protein containing moderate amounts of isoflavones (ISP56)
Number of subjects: 66
Study 9734729 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated soy protein containing high amounts of isoflavones (ISP90)
Number of subjects: 66
Study 9734729 — intervention group
Group type: COMPARATOR
Intervention: Control group (NCEP Step 1 diet with protein from casein and nonfat dry milk)
Number of subjects: 66
Study 8036221 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodality treatment using oliphenum, prednisolone or their combination
Number of subjects: 60
Study 31722404 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS (10 Hz, 1,500 stimuli)
Number of subjects: 48
Study 31722404 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 48
Study 30594934 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency stimulation (LFS) at 60 Hz and 80 Hz
Number of subjects: 15
Study 30594934 — intervention group
Group type: COMPARATOR
Intervention: High frequency stimulation (HFS) at 110 Hz, 130 Hz, and 200 Hz
Number of subjects: 15
Study 28843241 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN with intravenous sodium glycerophosphate (Glycophos) 1.5 mmol/kg/day
Number of subjects: 0
Study 28843241 — intervention group
Group type: COMPARATOR
Intervention: TPN without sodium glycerophosphate
Number of subjects: 0
Study 25791025 — intervention group
Group type: EXPERIMENTAL
Intervention: Central site particle number concentration (PNC)
Number of subjects: 2
Study 25791025 — intervention group
Group type: COMPARATOR
Intervention: Near-highway and predicted residential PNC
Number of subjects: 2
Study 23795788 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral enucleation and resection of the prostate (TUERP)
Number of subjects: 100
Study 23795788 — intervention group
Group type: COMPARATOR
Intervention: Transvesical prostatectomy (TVP)
Number of subjects: 100